These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2250347)

  • 1. [Interactions of radiation and biological response modifiers (BRMs) in the treatment of malignant tumor].
    Mitsuhashi N; Takahashi M; Okazaki A; Niibe H
    Gan No Rinsho; 1990 Oct; 36(13):2272-7. PubMed ID: 2250347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of biological response modifiers (BRMs) combined with radiotherapy].
    Mitsuhashi N; Okazaki A; Kawashima M; Niibe H
    Gan No Rinsho; 1988 Oct; 34(13):1816-20. PubMed ID: 2848957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer therapy by biological response modifiers.
    Herberman RB
    Arzneimittelforschung; 1987 Feb; 37(2A):246-50. PubMed ID: 2436633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy of cancer: biological response modifiers and cytotoxic cell therapy.
    Hillman GG; Haas GP; Wahl WH; Callewaert DM
    Biotherapy; 1992; 5(2):119-29. PubMed ID: 1524952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Differences in antitumor effect of various BRMs by intratumoral administration: induction of immunosuppressive acidic protein].
    Ebina T; Murata K
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1453-6. PubMed ID: 8373204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo and in vivo characterization of biological response modifiers (BRMs).
    Masihi KN; Talmadge JE
    Dev Biol Stand; 1992; 77():143-5. PubMed ID: 1426655
    [No Abstract]   [Full Text] [Related]  

  • 8. New antineoplastic therapies and inherent risks: monoclonal antibodies, biologic response modifiers and interleukin-2.
    Dillman JB
    J Intraven Nurs; 1989; 12(2):103-13. PubMed ID: 2475596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines and cancer: experimental systems.
    Blankenstein T; Rowley DA; Schreiber H
    Curr Opin Immunol; 1991 Oct; 3(5):694-8. PubMed ID: 1755987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differences of antitumor effect of various BRMs by intratumoral administration].
    Ebina T; Murata K
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1429-32. PubMed ID: 1530288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemical modifiers in radiotherapy].
    Nagashima T; Takakura K
    Gan No Rinsho; 1989 Sep; 35(11):1369-71. PubMed ID: 2681875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination of chemotherapy and immunotherapy in man--review].
    Ohnuma T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1428-36. PubMed ID: 1697154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined radiation therapy and dendritic cell vaccine for treating solid tumors with liver micro-metastasis.
    Chen Z; Xia D; Bi X; Saxena A; Sidhu N; El-Gayed A; Xiang J
    J Gene Med; 2005 Apr; 7(4):506-17. PubMed ID: 15580588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].
    Kan N; Okino T; Satoh K; Mise K; Teramura Y; Yamasaki S; Harada T; Ohgaki K; Tobe T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1421-7. PubMed ID: 2389941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacteria and biological response modifiers: two sides of the relationship.
    Sundareshan V; Modi J; Khardori NM
    Infect Dis Clin North Am; 2011 Dec; 25(4):865-93. PubMed ID: 22054761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of BRMs with chemotherapy.
    Tursz T
    Am J Med; 1995 Dec; 99(6A):56S-58S. PubMed ID: 8585538
    [No Abstract]   [Full Text] [Related]  

  • 18. Combining radiation therapy with interleukin-3 gene immunotherapy.
    Chiang CS; Hong JH; Wu YC; McBride WH; Dougherty GJ
    Cancer Gene Ther; 2000 Aug; 7(8):1172-8. PubMed ID: 10975678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2.
    Pippin BA; Rosenstein M; Jacob WF; Chiang Y; Lotze MT
    Cancer Gene Ther; 1994 Mar; 1(1):35-42. PubMed ID: 7621236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunomodulation in cancer. What do we do and where do we go?].
    Rodríguez Orozco AR; Serriteño NM
    Rev Alerg Mex; 2005; 52(2):96-101. PubMed ID: 16158783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.